AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)
23.74 USD
-0.550 2.264%Sponsored Reports
Loading...
| Previous Close (in USD) | 24.29 |
|---|---|
| Change | -0.550 2.264% |
| 52 W H/L (in USD) | 17.495/11.090 |
| EBITDA (in USD) | 114.04M |
| PE Ratio | 28.57 |
| Volume | 534224 |
| Diluted Eps TTM | 0.58 |
| Total Assets (in USD) | 471.907M |
|---|---|
| Total Liabilities (in USD) | 84.026M |
| Revenue TTM (in USD) | 411.347M |
| Cash (in USD) | 137.636M |
| Market Cap (in USD) | 1,957.166 M |
| Revenue Per Share TTM | 3.771 |
| Gross Profit TTM (in USD) | 160.021M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
355 Alhambra Circle, Coral Gables, FL, United States, 33134
305 420 3200
Employees: 167
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Patrick J. McEnany | Co-Founder, Chairman, Pres & CEO | 1947 |
| 2. | Ms. Alicia Grande C.M.A., CPA, CMA, CPA | Chief Accounting Officer, VP, Treasurer & CFO | 1971 |
| 3. | Dr. Steven R. Miller Ph.D. | COO & Chief Scientific Officer | 1962 |
| 4. | Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer | 1956 |
| 5. | Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 1976 |
| 6. | Ms. Mary Coleman | VP & Head of Investor Relations | NA |
| 7. | Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 1964 |
| 8. | Mr. Pete Curry Sr. | VP of Sales | NA |
| 9. | Mr. Jeffrey Del Carmen | Chief Commercial Officer | 1971 |
| 10. | Mr. Philip B. Schwartz | Corp. Sec. | 1955 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 104.719M | 52.667M | 41.89M | 33.409M | -34.004M |
| Minority Interest | - | - | - | - | - |
| Net Income | 83.079M | 39.482M | 74.983M | 31.875M | -34.004M |
| Selling General Administrative | 28.714M | 23.477M | 20.667M | 36.881M | 15.876M |
| Gross Profit | 179.81M | 118.949M | 102.034M | 87.547M | 0.5M |
| Reconciled Depreciation | 1.239M | 0.192M | 0.885M | 0.298M | 0.038M |
| Ebit | 100.599M | 52.193M | 40.418M | 31.526M | -35.333M |
| Ebitda | 101.838M | 52.385M | 41.303M | 31.823M | -35.295M |
| Depreciation And Amortization | 1.239M | 0.192M | 0.885M | 0.298M | 0.038M |
| Operating Income | 101.838M | 52.385M | 41.303M | 31.823M | -35.295M |
| Other Operating Expenses | 112.365M | 88.448M | 77.77M | 70.483M | 35.795M |
| Interest Expense | -4.12M | 0.474M | 1.472M | 1.884M | 1.292M |
| Tax Provision | 21.64M | 13.185M | -33.093M | 1.534M | 0M |
| Interest Income | - | - | - | 1.586M | 1.292M |
| Net Interest Income | - | - | - | 1.586M | 1.292M |
| Income Tax Expense | 21.64M | 13.185M | -33.093M | 1.534M | 2.583M |
| Total Revenue | 214.203M | 140.833M | 119.073M | 102.306M | 0.5M |
| Total Operating Expenses | 77.972M | 66.564M | 60.73M | 55.724M | 35.795M |
| Cost Of Revenue | 34.393M | 21.884M | 17.039M | 14.759M | 19.919M |
| Total Other Income Expense Net | 2.881M | 0.282M | 0.587M | 1.586M | 1.292M |
| Net Income From Continuing Ops | 83.079M | 39.482M | 74.983M | 31.875M | -34.004M |
| Net Income Applicable To Common Shares | 83.079M | 39.482M | 74.983M | 31.875M | -34.004M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 471.907M | 375.63M | 237.788M | 192.354M | 112.376M |
| Intangible Assets | 194.049M | 32.471M | - | - | - |
| Other Current Assets | 12.535M | 5.158M | 4.351M | 8.328M | 4.351M |
| Total Liab | 84.026M | 75.209M | 30.957M | 22.756M | 24.746M |
| Total Stockholder Equity | 387.881M | 300.421M | 206.831M | 169.598M | 87.63M |
| Other Current Liab | 60.17M | 53.276M | 0.243M | 0.107M | 0.172M |
| Common Stock | 0.107M | 0.105M | 0.103M | 0.104M | 0.103M |
| Capital Stock | 0.107M | 0.105M | 0.103M | 0.104M | 0.103M |
| Retained Earnings | 121.272M | 49.862M | -26.31M | -53.706M | -128.689M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 18.745M | 23.706M | 32.98M | 0.009M |
| Cash | 137.636M | 298.395M | 171.445M | 130.237M | 89.512M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 76.063M | 57.588M | 27.063M | 22.756M | 24.099M |
| Current Deferred Revenue | 0.729M | - | 23.744M | 18.364M | 19.508M |
| Net Debt | -134.079M | -294.501M | -167.551M | -130.237M | -88.864M |
| Short Term Debt | 0.369M | 0.337M | 0.308M | 0.029M | 0.301M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 3.557M | 3.894M | 3.894M | 0.029M | 0.648M |
| Other Stockholder Equity | 266.488M | 250.43M | 233.186M | 223.168M | 216.206M |
| Property Plant Equipment | - | 0.847M | 3.976M | 0.13M | 0.21M |
| Total Current Assets | 219.329M | 320.797M | 210.106M | 159.244M | 111.364M |
| Long Term Investments | 16.489M | - | - | - | 0M |
| Short Term Investments | - | 0M | 19.821M | 10.041M | 5.007M |
| Net Receivables | 53.514M | 10.439M | 6.619M | 5.987M | 10.537M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 15.644M | 6.805M | 7.87M | 4.651M | 1.957M |
| Accounts Payable | 14.795M | 3.975M | 2.768M | 4.256M | 4.117M |
| Accumulated Other Comprehensive Income | 0.014M | 0.024M | -0.148M | 0.031M | 0.01M |
| Non Currrent Assets Other | -0M | 0.009M | 0.009M | 0.009M | 0.009M |
| Non Current Assets Total | 252.578M | 54.833M | 27.682M | 33.11M | 1.013M |
| Capital Lease Obligations | 3.557M | 3.894M | 3.894M | 0.029M | 0.948M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -255.184M | 19.238M | -10M | -5.011M | 37.244M |
| Total Cashflows From Investing Activities | - | 9.209M | -11.021M | -5.011M | 37.225M |
| Total Cash From Financing Activities | -10.857M | 1.694M | -8.143M | 0.702M | 1.116M |
| Net Income | 71.41M | 83.079M | 39.482M | 74.983M | 31.875M |
| Change In Cash | -160.759M | 126.95M | 41.208M | 40.725M | 72.952M |
| Begin Period Cash Flow | 298.395M | 171.445M | 130.237M | 89.512M | 16.559M |
| End Period Cash Flow | 137.636M | 298.395M | 171.445M | 130.237M | 89.512M |
| Total Cash From Operating Activities | 143.6M | 116.047M | 60.372M | 45.035M | 34.611M |
| Depreciation | 33.143M | 1.239M | 0.192M | 0.885M | 0.298M |
| Other Cashflows From Investing Activities | - | -10M | - | - | 37.244M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -4.739M | 1.065M | -3.219M | -2.694M | -1.901M |
| Sale Purchase Of Stock | -0.982M | -6.907M | -12.089M | -0.056M | 1.116M |
| Other Cashflows From Financing Activities | -13.649M | 4.502M | -0.153M | -0M | 1.116M |
| Capital Expenditures | 198.524M | 0.029M | 1.021M | 0.011M | 0.019M |
| Change In Working Capital | -37.324M | 13.729M | 5.022M | -4.111M | -1.096M |
| Other Non Cash Items | 79.939M | 5.156M | 0.287M | -0.012M | -0.291M |
| Free Cash Flow | -54.924M | 116.018M | 59.351M | 45.023M | 34.592M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 1 year ago | 7517808 |
| 2. | SPDR® S&P Biotech ETF | 1 year ago | 3779302 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 3538816 |
| 4. | iShares Russell 2000 ETF | 1 year ago | 2576894 |
| 5. | First Trust NYSE Arca Biotech ETF | 1 year ago | 2425906 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1660274 |
| 7. | iShares S&P Small-Cap 600 Growth ETF | 1 year ago | 1086859 |
| 8. | Fidelity Small Cap Index | 1 year ago | 1025058 |
| 9. | SPDR® Portfolio S&P 600 Sm Cap ETF | 1 year ago | 985587 |
| 10. | iShares Russell 2000 Growth ETF | 1 year ago | 944199 |
| 11. | T. Rowe Price Integrated US Sm Gr Eq | 1 year ago | 890500 |
| 12. | Vanguard Tax-Managed Small Cap Adm | 1 year ago | 862435 |
| 13. | DFA US Micro Cap I | 1 year ago | 713683 |
| 14. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 681171 |
| 15. | Janus Henderson Global Life Sciences | 1 year ago | 672701 |
| 16. | Janus Henderson Global Life Sciences D | 1 year ago | 672701 |
| 17. | Fidelity Extended Market Index | 1 year ago | 648824 |
| 18. | SPDR® S&P 600 Small Cap Growth ETF | 1 year ago | 612764 |
| 19. | DFA US Small Cap I | 1 year ago | 579289 |
| 20. | Royce Small-Cap Fund Invmt | 1 year ago | 571578 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 15822299 |
| 2. | Vanguard Group Inc | 1 year ago | 7980661 |
| 3. | State Street Corporation | 1 year ago | 6787332 |
| 4. | Dimensional Fund Advisors, Inc. | 1 year ago | 2737657 |
| 5. | HHG PLC | 1 year ago | 2726388 |
| 6. | Geode Capital Management, LLC | 1 year ago | 2200225 |
| 7. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1961539 |
| 8. | Goldman Sachs Group Inc | 1 year ago | 1916826 |
| 9. | Royce & Associates, LP | 1 year ago | 1743074 |
| 10. | Renaissance Technologies Corp | 1 year ago | 1597427 |
| 11. | Boston Partners Global Investors, Inc | 1 year ago | 1506930 |
| 12. | Northern Trust Corp | 1 year ago | 1418741 |
| 13. | Opaleye Management Inc | 1 year ago | 1257200 |
| 14. | Jacobs Levy Equity Management, Inc. | 1 year ago | 1255880 |
| 15. | T. Rowe Price Associates, Inc. | 1 year ago | 1219418 |
| 16. | Charles Schwab Investment Management Inc | 1 year ago | 1075559 |
| 17. | Amvescap Plc. | 1 year ago | 919647 |
| 18. | LSV Asset Management | 1 year ago | 896000 |
| 19. | Jupiter Asset Management Limited | 1 year ago | 843931 |
| 20. | Bank of New York Mellon Corp | 1 year ago | 789621 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...